Where to begin? With a prime example from the legal adult-use industry.
Do you prefer indica or sativa?
In cannabis retail stores across Canada and dispensaries in the US, products are typically categorised into indica-dominant, sativa-dominant or hybrid. Cannabis consultants – or budtenders – will advise consumers to expect an indica-dominant product, to produce a sedating effect, possibly even leading to ‘couch-lock’ and therefore best consumed in the evening. Indica = In da couch.
A sativa-dominant high is likely to be more energising or alerting and better suited for daytime consumption. With a hybrid, you can expect a combination of effects; depending on the ratio of indica to sativa – whatever that means!
The problem? It’s outdated nonsense.
I know this all too well as I was responsible for teaching it to retail staff in cannabis stores across British Columbia, believing it to be world class cannabis education. The truth is indica and sativa are terms used to describe the morphology of the plant and have no bearing on the expected effects on the consumer. The cannabinoid and terpene profiles of a particular chemovar of cannabis are a better indicator of gauging expected effects.
To add to that, everyone’s endocannabinoid system is unique. Cannabis affects us all differently and there is a need for cautious, personal experimentation, to find a product that works for your desired effect. We also have to consider a consumer’s mindset and setting prior to consumption, as it will also play an important role in their overall cannabis experience; especially to a newbie.
So, why do cannabis retailers continue to sell cannabis in these categories? Because it’s easy! Sativa & indica are simple terms to understand. It makes life easy for the budtender, the consumer and the producers marketing the products. As straightforward as it is to understand, it does little to help consumers to find the right product for them. We are sacrificing a more complicated truth in place of unfounded ease at the expense of the consumer.
What about the CBD industry?
Unfortunately, we see the same issues arise in the CBD industry which is awash with misinformation. Let’s dive into some examples.
Almost every website mentioning CBD will tell you that it is a ‘non-psychoactive’ compound. But, according to Dr. Ethan Russo, this is an inaccurate term, given its prominent pharmacological benefits on anxiety, schizophrenia, addiction, and possibly even depression. More accurately, we should be describing CBD as ‘non-intoxicating’.1
Am I being too pedantic here? Possibly. But if you’re not onboard with giving out correct information to your consumers, you’re part of the problem.
In the UK, it is widely believed that the limit of THC in legal CBD products is 0.2%, but this is also a common misconception. The 0.2% THC threshold refers to various rules in relation to cultivation and import of hemp. Under the Misuse of Drugs Regulations 2001, ‘exempt product’ status allows for the presence of no more than 1mg of THC in any given CBD product – although this now appears to be under review.
Add to the above the many unsubstantiated medical claims; CBD being hailed as a cure all and bogus products like CBD pillows, being sold to vulnerable people genuinely seeking relief from CBD, and it’s not a good look for the industry.
These examples are by no means an exhaustive list, but they are an indication that we as an industry need to do better, and to consistently give out the most up to date information to consumers. The cannabis industry is evolving at a fierce pace, and we have only scratched the surface on what we know about this powerful plant.
For the industry to progress in a better way, we need to be agile in our knowledge and education for the benefit of the consumer. Whether you’re involved in the medical, wellness or recreational side of the cannabis industry, the focus should always be on the end user experience.
Sativa Learning was created with the aims of providing the most up to date and accurate cannabis training and education available. Our CBD Industry Professional course has been developed by industry experts and includes a legal module which is reviewed and approved every quarter by Mackrell Solicitors, ensuring you receive the most current knowledge available.
We’re accredited by the CPD certification service to guarantee the content has been created to the highest standards of further learning. We are committed to providing cannabis organisations, entrepreneurs, jobseekers, academics, and medical professionals with the tools needed to cultivate a career in the cannabis industry.
As the cannabis industry grows worldwide, the gap in cannabis knowledge grows with it. We are here to bridge that gap.
Enrol in your next CPD accredited, CBD course today; or get in touch with us for more information.
SPONSORED: Tackling misinformation in the cannabis industry
Where to begin? With a prime example from the legal adult-use industry.
Do you prefer indica or sativa?
In cannabis retail stores across Canada and dispensaries in the US, products are typically categorised into indica-dominant, sativa-dominant or hybrid. Cannabis consultants – or budtenders – will advise consumers to expect an indica-dominant product, to produce a sedating effect, possibly even leading to ‘couch-lock’ and therefore best consumed in the evening. Indica = In da couch.
A sativa-dominant high is likely to be more energising or alerting and better suited for daytime consumption. With a hybrid, you can expect a combination of effects; depending on the ratio of indica to sativa – whatever that means!
The problem? It’s outdated nonsense.
I know this all too well as I was responsible for teaching it to retail staff in cannabis stores across British Columbia, believing it to be world class cannabis education. The truth is indica and sativa are terms used to describe the morphology of the plant and have no bearing on the expected effects on the consumer. The cannabinoid and terpene profiles of a particular chemovar of cannabis are a better indicator of gauging expected effects.
To add to that, everyone’s endocannabinoid system is unique. Cannabis affects us all differently and there is a need for cautious, personal experimentation, to find a product that works for your desired effect. We also have to consider a consumer’s mindset and setting prior to consumption, as it will also play an important role in their overall cannabis experience; especially to a newbie.
So, why do cannabis retailers continue to sell cannabis in these categories? Because it’s easy! Sativa & indica are simple terms to understand. It makes life easy for the budtender, the consumer and the producers marketing the products. As straightforward as it is to understand, it does little to help consumers to find the right product for them. We are sacrificing a more complicated truth in place of unfounded ease at the expense of the consumer.
What about the CBD industry?
Unfortunately, we see the same issues arise in the CBD industry which is awash with misinformation. Let’s dive into some examples.
Almost every website mentioning CBD will tell you that it is a ‘non-psychoactive’ compound. But, according to Dr. Ethan Russo, this is an inaccurate term, given its prominent pharmacological benefits on anxiety, schizophrenia, addiction, and possibly even depression. More accurately, we should be describing CBD as ‘non-intoxicating’.1
Am I being too pedantic here? Possibly. But if you’re not onboard with giving out correct information to your consumers, you’re part of the problem.
In the UK, it is widely believed that the limit of THC in legal CBD products is 0.2%, but this is also a common misconception. The 0.2% THC threshold refers to various rules in relation to cultivation and import of hemp. Under the Misuse of Drugs Regulations 2001, ‘exempt product’ status allows for the presence of no more than 1mg of THC in any given CBD product – although this now appears to be under review.
Add to the above the many unsubstantiated medical claims; CBD being hailed as a cure all and bogus products like CBD pillows, being sold to vulnerable people genuinely seeking relief from CBD, and it’s not a good look for the industry.
These examples are by no means an exhaustive list, but they are an indication that we as an industry need to do better, and to consistently give out the most up to date information to consumers. The cannabis industry is evolving at a fierce pace, and we have only scratched the surface on what we know about this powerful plant.
For the industry to progress in a better way, we need to be agile in our knowledge and education for the benefit of the consumer. Whether you’re involved in the medical, wellness or recreational side of the cannabis industry, the focus should always be on the end user experience.
Sativa Learning was created with the aims of providing the most up to date and accurate cannabis training and education available. Our CBD Industry Professional course has been developed by industry experts and includes a legal module which is reviewed and approved every quarter by Mackrell Solicitors, ensuring you receive the most current knowledge available.
We’re accredited by the CPD certification service to guarantee the content has been created to the highest standards of further learning. We are committed to providing cannabis organisations, entrepreneurs, jobseekers, academics, and medical professionals with the tools needed to cultivate a career in the cannabis industry.
As the cannabis industry grows worldwide, the gap in cannabis knowledge grows with it. We are here to bridge that gap.
Enrol in your next CPD accredited, CBD course today; or get in touch with us for more information.
Relm Risk Briefing: Cannabis 2026
The global cannabis sector has moved from experiment to enterprise. This comprehensive risk briefing examines how regulation, insurance, and operational practices intersect across the international supply chain, drawing on insights from RELM—the only insurer entirely dedicated to the cannabis industry.
What's covered
Key insights
Download Relm Risk Briefing: Cannabis 2026
Get your free copy of the comprehensive risk analysis report.
CBD market value balloons as UK undergoes ‘quiet cannabis revolution’
Next PostHow complex tech is being used to revolutionise hemp farming
Sponsored content editor
Related Posts
Related Posts
UK CBD Approvals Face Autumn 2026 Crunch as Industry Proposes Framework Overhaul
The UK's first-ever CBD product authorisations, originally expected to be completed by Autumn 2026, could now face another setback as...
France Extends Medical Cannabis Access Again as Full Access Bill Remains Stuck in Limbo
Thousands of French medical cannabis patients will continue to receive their treatment for the foreseeable future, as the highly anticipated...
The Battle for Germany’s Medical Cannabis Market: Who’s Fighting for What
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
Industry Leaders React to Historic Cannabis Rescheduling
Cannabis Europa Paris
Europe’s leading cannabis policy, business and investment conference — bringing senior decision-makers together in Paris.
CONNECT
Related Posts
Related Posts
UK CBD Approvals Face Autumn 2026 Crunch as Industry Proposes Framework Overhaul
The UK's first-ever CBD product authorisations, originally expected to be completed by Autumn 2026, could now face another setback as...
France Extends Medical Cannabis Access Again as Full Access Bill Remains Stuck in Limbo
Thousands of French medical cannabis patients will continue to receive their treatment for the foreseeable future, as the highly anticipated...
The Battle for Germany’s Medical Cannabis Market: Who’s Fighting for What
Today, (Wednesday, January 14), a public hearing will bring together 22 hand-picked experts for a debate on the future country's...
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs' Council has approved the first...
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
As Trump's rescheduling executive order dominated the cannabis industry’s attention over the holiday period, Germany's controversial medical cannabis bill quietly...
Recent Posts
Related Posts
Spanish Pharmacists Appeal Hospital-Only Cannabis Rule as Key Regulatory Deadline Passes Unmet
Spain represents one of the most exciting incoming additions to the European medical cannabis market this year, as one of...
Inside the Medical Cannabis Police Guidance: Cancards, Driving, and What Patients Need to Know
Earlier this week, the first official guidance on medical cannabis for police officers in England and Wales was made public. Its...
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs' Council has approved the first...
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
As Trump's rescheduling executive order dominated the cannabis industry’s attention over the holiday period, Germany's controversial medical cannabis bill quietly...
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump's executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags